Role of the Wnt/b-Catenin Pathway Inhibitor Sclerostin in Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)

2018 ◽  
Vol 5 ◽  
pp. 19-24
Author(s):  
Chao Zheng ◽  
Huang Ding ◽  
Linjun Qin ◽  
Ali Xiong ◽  
Jiulong Wang ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Mineral And Bone Disorder ◽  
Bone Disorder

Update on imaging in chronic kidney disease-mineral and bone disorder: promising role of functional imaging

2021 ◽  
Author(s):  
Sharjeel Usmani ◽  
Najeeb Ahmed ◽  
Gopinath Gnanasegaran ◽  
Fahad Marafi ◽  
Tim van den Wyngaert
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Functional Imaging ◽  
Mineral And Bone Disorder ◽  
Bone Disorder

Role of Uremic Toxins and Oxidative Stress in the Development of Chronic Kidney Disease–Mineral and Bone Disorder

2012 ◽  
Vol 22 (1) ◽  
pp. 98-101 ◽  
Author(s):  
Hisae Tanaka ◽  
Hirotaka Komaba ◽  
Masahiro Koizumi ◽  
Takatoshi Kakuta ◽  
Masafumi Fukagawa
Keyword(s):  
Oxidative Stress ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Uremic Toxins ◽  
Mineral And Bone Disorder ◽  
Bone Disorder ◽  
And Oxidative Stress

Potential effect of pharmaceutical care to improve outcomes in patients with chronic kidney disease-mineral bone disorder in Sulaimani dialysis centers

2020 ◽  
pp. 82-94
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Pharmaceutical Care ◽  
Biochemical Parameters ◽  
Positive Impact ◽  
Potential Effect ◽  
Care Group ◽  
Mineral Bone Disorder ◽  
Bone Disorder

Objective: the present study was aimed to evaluate the role of pharmaceutical services in improving the outcome of mineral bone disorder in patients with advanced chronic kidney disease. Methodology: One hundred and twenty patients with chronic kidney disease-mineral bone disorder (CKD-MBD) screened for eligibility, seventy-six patients enrolled in the study and randomly allocated into two groups: pharmaceutical care and usual care, both groups interviewed by the pharmacist using specific questionnaire for assessing the quality of life (QoL). All the drug related problems (DRPs) including drug-drug interactions (DDIs) were recorded by the pharmacist. Blood samples were collected and utilized for analyzing the levels of vitamin D, phosphorous, calcium, albumin and parathyroid hormone at baseline and three months after. The pharmaceutical care group received all the educations about their medications and how to minimize DRPs; improve the QoL. Additionally, the pharmaceutical intervention included correcting the biochemical parameters. Results: Pharmaceutical care significantly improved patients QoL and minimized DRPs and DDIs. It was also effective in improving the biochemical parameters. Conclusion: Pharmaceutical care has a positive impact on improving the outcome of patients with CKD-MBD through attenuating DRPs, improving the biochemical parameters and the QoL.

scholarly journals Bone health in chronic kidney disease-mineral and bone disorder: a clinical case seminar and update

2018 ◽  
Vol 48 (12) ◽  
pp. 1435-1446 ◽  
Author(s):  
Jasna Aleksova ◽  
Kong W. Ng ◽  
Caroline Jung ◽  
Howard Zeimer ◽  
Karen M. Dwyer ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Bone Health ◽  
Clinical Case ◽  
Mineral And Bone Disorder ◽  
Bone Disorder

Assessment of bone turnover markers to predict mineral and bone disorder in men with pre-dialysis non-diabetic chronic kidney disease

2017 ◽  
Vol 469 ◽  
pp. 195-200 ◽  
Author(s):  
Joseph Jessy Davina ◽  
M. Priyadarssini ◽  
Medha Rajappa ◽  
Sreejith Parameswaran ◽  
Jayaprakash Sahoo ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Bone Turnover ◽  
Bone Turnover Markers ◽  
Mineral And Bone Disorder ◽  
Bone Disorder ◽  
Turnover Markers
Sign in / Sign up

Export Citation Format

Share Document